Once Patent Protection Is Lost, Imatinib as Initial Treatment for CP-CML Will Be Most Cost-effective Strategy

Share this content:
Imatinib will become the cost-effective initial treatment strategy administered to patients with chronic phase chronic myeloid leukemia.
Imatinib will become the cost-effective initial treatment strategy administered to patients with chronic phase chronic myeloid leukemia.

Imatinib, which will have a generic version available this year in the United States, will become the cost-effective initial treatment strategy administered to patients with chronic phase chronic myeloid leukemia (CML-CP), investigators predicted.1

The price is expected to drop anywhere from 70% to 90%. Investigators researched whether initiating treatment with generic imatinib , then switching to other tyrosine kinase inhibitors dasatinib or nilotinib, due to lack of tolerance or response, would be cost-effective compared with the current standard of care, which is physician's choice of initial tyrosine kinase inhibitor therapy.

Investigators constructed Markov models to compare the 5-year cost-effectiveness of imatinib vs physician's choice from a consumer standpoint, assuming 3% annual discounting ($2013). The model's endpoint was 5-year overall survival taken from a systematic review of clinical trial results.

Truven's MarketScan claims data were used to estimate per-person cost on incident CML-CP treatment overall care components. Main outcome of the models was cost per quality-adjusted life-year (QALY). Outcomes were interpreted based on a willingness-to-pay threshold of $100 000/QALY.

RELATED: Cytomegalovirus After HCT Does Not Protect Against Leukemia Relapse

Results showed that both strategies met the threshold. Imatinib-first gave patients a 0.10 decrement in QALYs at a savings of $88 343 over 5 years compared with physicians choice ($365 744, 3.97 QALYs). Imatinib-first incremental cost-effectiveness ratio was about $883 730/QALY.

Reference

  1. Padula WV, Larson RA, Dusetzina SB, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7): doi: 10.1093/jnci/djw003.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters